|
Postpartum depression
|
− Zuranolone was found to enhance HAMD-17 scores and alleviate depression symptoms in women with PPD by day 15, compared to a placebo. These effects were noticeable from day 3 and persisted up to 45 days. Additionally, patients reported better anxiety, global, and maternal functioning. In MDD patients, a 14-day zuranolone treatment reduced depressive symptoms as per the HAM-D score (2).
|
|
Major depressive disorder
|
− In a double-blind trial with 543 major depressive disorder patients, zuranolone (50 mg daily) showed significant symptom reduction by day 15, with effects noticeable by day 33. The drug was safe, well-tolerated, and presented no new safety concerns (10).
|
|
Insomnia
|
− Zuranolone, as a treatment for insomnia, was tested in a study where patients received either a 30 mg or 45 mg dose, or a placebo. Results showed significant improvements in sleep quality and efficiency, with higher doses yielding better outcomes. The treatment increased time spent in N2 and N3 sleep stages, but not in N1 or R stages (5).
|
|
Parkinson’s tremor
|
− In an open-label, exploratory study, zuranolone was administered to 14 patients with Parkinson’s disease who were already receiving stable doses of other medications. Zuranolone improved tremor symptoms as early as 12 h following the first dose and was sustained throughout the treatment period. Similar improvements were noted in overall experiences of daily living and medication-related motor complications. Zuranolone was generally well-tolerated, with the most common adverse events being headache and fatigue (9).
|
|
Bipolar disorder
|
− Zuranolone has shown promising results in an open-label, phase 2 study of 30 mg daily for 2 weeks in bipolar disorder patients with depressive symptoms. It improved mood, anxiety, and functioning, and was well-tolerated. However, more studies are needed to confirm its efficacy and safety (11).
|
